Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol-Myers multiple myeloma combo therapy fails late-stage study

Bristol Myers Squibb Co said on Monday its combination therapy for multiple myeloma did not meet the main goal of showing an…

Bristol-Myers Squibbs Empliciti flunks first-line MM study

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers shares slide 4% premarket on news of failed trial of multiple myeloma treatment

Bristol-Myers Squibb Co. shares slid 4% in premarket trade Monday, after the drug company said a late-stage trial of…

The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Biotech stocks rebounded in the week ended March 6, recovering from the previous weeks steep sell-off. The week was light on…

Bristol-Myers Squibb (BMY) Stock Moves -1.59%: What You Should Know

Bristol-Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.59% move from the prior day....…

Bristol-Myers Named a Bank of America Top Pick Amid Coronavirus Fallout

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla MSI test in China

PRESS RELEASE                                                                                            5 March 2020, 07:01 CET...…

Bristol-Myers Squibb: Market Uncertainty Makes For A (Potential) Buying Opportunity

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb (BMY) Stock Moves -0.87%: What You Should Know

Bristol-Myers Squibb (BMY) closed at $59.06 in the latest trading session, marking a -0.87% move from the prior day....…

Bristol-Myers Liso-Cel Given Priority Review, Ability To Change Scope Of Treatment

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy-

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Bristol-Myers study expansions triggers $10M payment to CytomX

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

A Big Month Ahead for the FDA and Bristol-Myers Squibb

Success for the Celgene merger rests heavily on new drug approvals the U.S. Food and Drug Administration could deliver in…

Bristol-Myers Squibb Makes Case For Success Of Opdivo With Latest Long-Term Kidney Cancer Data

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Compugen expands agreement with BMS

Israeli drug discovery company Compugen is conducting three cancer treatment trials this year, two of them with Bristol-Myers Squibb....…

Bristol-Myers Squibb: Up 50% In 6 Months, But It Can Continue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Opdivo delivers superior five-year survival results in renal cell carcinoma

The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five…

Better Buy: GlaxoSmithKline vs. Bristol-Myers Squibb

Which of these top pharma stocks is the better buy right now?...…

Better Buy: Biogen vs. Bristol-Myers Squibb

Does the potential of a home run for Biogen with its Alzheimers disease candidate outweigh the strong lineup and pipeline…

Bristol-Myers (BMY) CAR T Cell Therapy Gets Priority Review

Bristol-Myers (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA....…

The US FDA accepts for priority review Bristol-Myers Squibbs BLA for liso-cel for adult patients with relapsed or refractory large B-cell lymphoma

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020. "There remains a…

FDA Gives Bristol-Myers Squibbs CAR-T Liso-Cel a Priority Review

A decision on the cancer therapy is expected by Aug. 17....…

Bristol-Myers Squibbs liso-cel fast tracked in U.S. for large B-cell lymphoma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Building A Hedged Portfolio Around Bristol-Myers Squibb

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

The Zacks Analyst Blog Highlights: Alibaba, Toyota Motor, Bristol-Myers Squibb, S&P Global and Uber Technologies

The Zacks Analyst Blog Highlights: Alibaba, Toyota Motor, Bristol-Myers Squibb, S&P Global and Uber Technologies...…

Bristol-Myers Squibb Stock Is Too Cheap to Ignore

The acquisition of Celgene is working wonders so far....…

Sell-siders on board with Bristol-Myers Squibbs Q4 & outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

This is Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results....…

Bristol-Myers (BMY) Q4 Earnings & Revenues Beat Estimates

Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition…

Bristol-Myers Squibb Co (BMY) Q4 2019 Earnings Call Transcript

BMY earnings call for the period ending December 31, 2019....…

Bristol-Myers Squibb and Merck going opposite ways with PD-1 inhibitors

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibbs Earnings Get a Boost From Celgene Acquisition

The pharmaceutical giants guidance also looks good....…

Bristol-Myers Squibb Company 2019 Q4 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-Bristol-Myers earnings rise due to Celgene contribution

Bristol-Myers Squibb Co said on Thursday its operating profit rose by around a third from a year ago because fourth-quarter results included…

How Bristol-Myers Squibb Trounced Wall Streets Q4 Estimates

In a word: Celgene....…

Bristol-Myers Squibb schreibt nach Celgene-Kauf im Schlussquartal Verlust

NEW YORK (dpa-AFX) - Nach der Übernahme des Biopharmaspezialisten Celgene hat der Pharmakonzern Bristol-Myers Squibb im vierten Quartal einen Verlust…

Bristol-Myers Squibb schreibt nach Celgene-Kauf im Schlussquartal Verlust

NEW YORK (dpa-AFX) - Nach der Übernahme des Biopharmaspezialisten Celgene hat der Pharmakonzern Bristol-Myers Squibb …

Bristol-Myers: Celgene-Übernahme zahlt sich aus

Bristol-Myers: Celgene-Übernahme zahlt sich aus...…

Bristol-Myers +3% premarket on Q4 beat

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb reports 33% jump in Q4 revenue, Opdivo sales fall 2%

Shares of Bristol-Myers Squibb were up 2% in premarket trading on Thursday after the company beat earnings estimates for…

Bristol-Myers Tops Q4 Earnings Forecast As Celgene Takeover Boosts Bottom Line

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers earnings rise due to Celgene deal

Bristol-Myers Squibb Co said on Thursday its operating profit rose by around a third from a year ago because fourth-quarter results included…

Bristol-Myers Squibb EPS beats by $0.28, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

What Are Bristol-Myers Squibbs Top 3 Drugs-

Bristol-Myers Squibbs top 3 selling drugs (excluding that of Celgene) are Eliquis, Opdivo, and Orencia. These three drugs combined, likely…

Bristol-Myers Squibb, BioMotiv launch new biotechnology firm Anteros Pharmaceuticals

Yale University has developed the intellectual property behind Anteros and was first in-licenced by BMS and later authorised to Anteros.…

Bristol-Myers: Buy At The Highs

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings-

Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when…

Bristol-Myers and BioMotiv launch new drug venture

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Opdivo-Yervoy NSCLC Application in EU Withdrawn

Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced…